Dragon Claw Invited to be Part of A3BC
The burden of arthritis on the Australian population is huge band there is relatively little research being conducted locally to better understand how to diagnose, treat and cure arthritis. We aim to increase capacity for Australia to conduct world-class arthritis research by developing a ‘biobank’ of clinical data and bio-samples, supporting researchers to work in this field to find the best treatments and ultimately to find a cure.
Australian Arthritis and Autoimmune Disorders Biobank Collaborative (A3BC) is seeking support from the National Health and Medical Research Council (NHMRC). Dragon Claw have been invited because we provide a voice in patient related research and impact studies and also can communicate and disseminate research findings to our community.
Despite major advances in treatments, not all people respond, many develop significant side effects, and there remain no cures or preventions for these conditions. The Australian Arthritis and Autoimmune Collaborative (A3BC) was formed in 2016 by leading Rheumatology clinicians and scientists from over 40 sites across Australia to enable world-class translational research. The A3BC vision is to give the right treatment at the right time for the best possible outcomes in children and adults with arthritis conditions across their lifespan and, ultimately, to find a cure. The A3BC project will enable the infrastructure to educate and train A3BC clinicians and scientists, will generate new information for rheumatic diseases, and translate this new knowledge into policy and clinical practice.
The A3BC will link broad biospecimen-derived ‘omic’ data (from blood, synovial tissue and fluid, stool), patient reported outcomes, clinical disease phenotype, cross-jurisdictional electronic medical records, medical imaging, Commonwealth datasets (MBS, PBS, Cancer), national registries (ARAD) and longitudinal study data, into an integrated platform for rapid advancements to clinical care. The sophisticated biobanking, data integration and analytics, combined cutting-edge precision-preventive medicine approaches, and level of collaboration proposed by the A3BC-CRE will dramatically improve our understanding of the biology, causes and course of these conditions, and lead to better health for the Australian population.
Contact: Professor Lyn March